Detalhe da pesquisa
1.
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.
Lancet Oncol
; 23(9): 1167-1179, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35908558
2.
Influence of VEGFR2 gene polymorphism on the clinical outcomes of apatinib for patients with chemotherapy-refractory extensive-stage SCLC: a real-world retrospective study.
Int J Clin Oncol
; 26(4): 670-683, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33392882
3.
The mRNA of solute carrier family 22, member 17 (SLC22A17) plays the potential diagnostic and prognostic role in advantage non-small cell lung cancer patients.
Ann Biol Clin (Paris)
; 81(6): 602-609, 2024 02 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38391165
4.
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial.
Lancet Respir Med
; 12(3): 217-224, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38101437
5.
[Efficacy and safety of rh-endostatin combined with docetaxel in second-line or intolerant toxicity for first-line treatment in patients with advanced non-small cell lung cancer].
Zhonghua Zhong Liu Za Zhi
; 35(8): 618-22, 2013 Aug.
Artigo
em Zh
| MEDLINE | ID: mdl-24314222
6.
Difference of serum tumor markers in different clinical stages of elderly patients with non-small cell lung cancer and evaluation of diagnostic value.
J Med Biochem
; 42(4): 607-615, 2023 Oct 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38084245
7.
Exosomes derived from M1 macrophages inhibit the proliferation of the A549 and H1299 lung cancer cell lines via the miRNA-let-7b-5p-GNG5 axis.
PeerJ
; 11: e14608, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36643646
8.
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Respir Med
; 11(7): 624-636, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37156249
9.
Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial.
J Thorac Oncol
; 18(5): 628-639, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36646210
10.
Lung infection caused by Blastoschizomyces capitatus without immunodeficiency: a case report and review of the literature.
Ann Palliat Med
; 11(12): 3826-3832, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36636006
11.
A systematic review and meta-analysis of circulating cell-free DNA as a diagnostic biomarker for non-small cell lung cancer.
J Thorac Dis
; 14(6): 2103-2111, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35813759
12.
Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China.
Thorac Cancer
; 13(3): 412-422, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34935288
13.
Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study.
J Thorac Oncol
; 17(10): 1192-1204, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35724798
14.
Prophylactic cranial irradiation confers favourable prognosis for patients with limited-stage small cell lung cancer in the era of MRI: A propensity score-matched analysis.
J Med Imaging Radiat Oncol
; 65(6): 778-785, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34159731
15.
The role of autoantibody detection in the diagnosis and staging of lung cancer.
Ann Transl Med
; 9(22): 1673, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34988182
16.
Tumor-associated eosinophilia in a patient with EGFR-positive, MET-amplified lung adenocarcinoma refractory to targeted therapy: a case report and review of literature.
Transl Cancer Res
; 10(11): 4988-4996, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35116349
17.
Association Between PDL1 Genetic Variation and Efficacy of Apatinib Monotherapy in Patients with Previously Treated Advanced NSCLC: A Real-World Retrospective Study.
Int J Gen Med
; 14: 2703-2714, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34188525
18.
The Influence of KDR Genetic Variation on the Efficacy and Safety of Patients With Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen.
Technol Cancer Res Treat
; 20: 15330338211019433, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34060368
19.
Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC: A Single-Arm, Multicenter Phase 2 Study.
J Thorac Oncol
; 16(11): 1959-1963, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34265433
20.
Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study.
J Thorac Oncol
; 16(8): 1403-1414, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33915252